US0327241065
US0327241065
AnaptysBio, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|
Market & Enterprise Value | |||
Market Cap | 1.37B EUR | 1.07B EUR | 905.57M EUR |
Enterprise Value | 1.49B EUR | 838.51M EUR | 781.49M EUR |
Valuation Multiples | |||
Trailing P/E | -- | -- | -- |
Forward P/E | 9.07x | -- | -- |
Price to Sales | 12.95x | 4.62x | 3.86x |
Price to Book | 129.07x | 84.21x | 24.34x |
EV/Revenue | 14.02x | 3.61x | 3.33x |
EV/EBITDA | 22.63x | 14.34x | 11.29x |
Price to FCF (P/FCF) | -- | 243.45x | 46.18x |
EV/FCF | -- | 190.18x | 39.85x |
FCF Yield | -- | 0.41% | 2.17% |